ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating) by 39.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,173 shares of the company’s stock after purchasing an additional 5,392 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ImmunityBio were worth $97,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. MetLife Investment Management LLC boosted its stake in shares of ImmunityBio by 72.1% in the third quarter. MetLife Investment Management LLC now owns 44,059 shares of the company’s stock valued at $219,000 after purchasing an additional 18,454 shares during the period. ProShare Advisors LLC increased its holdings in shares of ImmunityBio by 6.2% in the 3rd quarter. ProShare Advisors LLC now owns 42,697 shares of the company’s stock valued at $212,000 after acquiring an additional 2,510 shares during the period. Liberty One Investment Management LLC increased its stake in ImmunityBio by 149.4% in the 3rd quarter. Liberty One Investment Management LLC now owns 30,122 shares of the company’s stock valued at $150,000 after buying an additional 18,042 shares during the period. Oracle Investment Management Inc. acquired a new position in ImmunityBio in the 3rd quarter valued at $1,567,000. Finally, Mayflower Financial Advisors LLC acquired a new position in ImmunityBio in the 4th quarter valued at $84,000. 9.86% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Trading Down 7.6 %

ImmunityBio stock opened at $5.92 on Wednesday. ImmunityBio, Inc. has a 52 week low of $1.21 and a 52 week high of $7.80. The firm’s 50-day simple moving average is $2.21 and its 200 day simple moving average is $3.92.

ImmunityBio Profile

(Get Rating)

ImmunityBio, Inc is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory.